A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee

• Published in: Osteoarthritis and cartilage Vol. 26; no. 1; pp. 18 - 27
• Main Authors: Deshmukh, V., Hu, H., Barroga, C., Bossard, C., KC, S., Dellamary, L., Stewart, J., Chiu, K., Ibanez, M., Pedraza, M., Seo, T., Do, L., Cho, S., Cahiwat, J., Tam, B., Tambiah, J.R.S., Hood, J., Lane, N.E., Yazici, Y.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2018
• Subjects: ACLT; Animals; Anti-Inflammatory Agents - pharmacokinetics; Anti-Inflammatory Agents - pharmacology; Cartilage, Articular - physiology; Cell Differentiation - drug effects; Cells, Cultured; Chondrocyte; Chondrocytes - cytology; Chondrocytes - drug effects; Dimethyl Sulfoxide - pharmacology; DMOAD; Imidazoles - pharmacokinetics; Imidazoles - pharmacology; Indazoles - pharmacokinetics; Indazoles - pharmacology; Male; Osteoarthritis; Osteoarthritis, Knee - drug therapy; Pyridines - pharmacokinetics; Pyridines - pharmacology; Rats, Sprague-Dawley; Regeneration - drug effects; Rheumatology; Small molecule; Solvents - pharmacology; Wnt signaling; Wnt Signaling Pathway - drug effects; Wnt signaling; DMOAD; Small molecule; Chondrocyte; ACLT; Osteoarthritis

Osteoarthritis (OA) is a degenerative disease characterized by loss of cartilage and increased subchondral bone within synovial joints. Wnt signaling affects the pathogenesis of OA as this pathway modulates both the differentiation of osteoblasts and chondrocytes, and production of catabolic proteas...